HIV Infections Clinical Trial
Official title:
Study to Test Meta-intervention to Increase Retention in HIV Prevention Counseling
| Verified date | June 2010 |
| Source | University of Illinois at Urbana-Champaign |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Unfortunately, people most at risk for HIV are the least likely to enroll and remain in
prevention programs. In our past work, we have learned how to increase enrollment in such
programs among this group. We have identified and addressed previously ignored
gender-specific and client self-validation issues that conventional interventions often leave
not only uncontrolled, but often biased against participation. The present work will extend
these methods from enrollment to retention.
We intend to recruit a sample of 656 at-risk participants through our collaboration with the
Duval County, FL Health Department for our randomized, double-blind trial. Our study will
investigate if a meta-intervention video designed for empowering participants as agents of
their own change can increase the number of attended sessions relative to a control condition
without such a video. This trial will also determine if a meta-intervention video addressing
various emotional/social and instrumental benefits of an HIV-prevention-counseling
intervention can also increase the number of attended sessions. These two factors will be
crossed, and their effects on retention will be estimated for different genders and
ethnicities. Effects on clients' attention to the return sessions as reported by the
counselor will also be explored among participants who return.
We will also conduct mediator analyses for investigating if the meta-intervention has
mediating influences on corresponding expectations about the return counseling session. As
the inclusion of meta-cognitive measures can alter the efficacy of the intervention, half of
the sample will receive measures immediately (0-10 minutes) after exposure to the
meta-intervention, before attendance to the next session is registered. The other half will
not complete these measures.
| Status | Completed |
| Enrollment | 722 |
| Est. completion date | April 30, 2017 |
| Est. primary completion date | April 30, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 35 Years |
| Eligibility |
Inclusion Criteria: - Sexually active, - Low condom use, - Low intention to use condom Exclusion Criteria: - Trying to get pregnant - HIV positive - with contaminant knowledge about the study - planning to leave the area |
| Country | Name | City | State |
|---|---|---|---|
| United States | Duval County Health Department | Jacksonville | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| University of Illinois at Urbana-Champaign | Duval County Health Department |
United States,
Albarracín D, Wilson K, Durantini MR, Sunderrajan A, Livingood W. A meta-intervention to increase completion of an HIV-prevention intervention: Results from a randomized controlled trial in the state of Florida. J Consult Clin Psychol. 2016 Dec;84(12):1052-1065. Epub 2016 Oct 27. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Enrollment | return rate for 2 upcoming sessions | 1 month | |
| Secondary | Perceptions of the counselor | Questionnaire measures of perceptions of the counseling session | 0-10 minutes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |